SEROSTIM LQ (somatropin) by Emergent BioSolutions is cells. First approved in 1996.
Drug data last refreshed 48m ago · AI intelligence enriched 2w ago
SEROSTIM LQ is a liquid formulation of somatropin (recombinant human growth hormone) approved in 1996 for subcutaneous injection. It works by binding to growth hormone receptors on cells, triggering intracellular signaling that induces IGF-1 production and stimulates protein synthesis, skeletal growth, and metabolic effects. The drug is indicated for growth hormone deficiency (GHD) in pediatric and adult patients, with effects on linear growth, protein synthesis, and hepatic glucose output.
As LOE approaches with moderate competitive pressure (30%), brand roles will shift from growth-focused strategies to defensive positioning and potential transition planning.
cells. This interaction results in intracellular signal transduction and subsequent induction of transcription and translation of GH-dependent proteins including IGF-1, IGF BP-3 and acid-labile subunit. Somatropin has direct tissue and metabolic effects or effects mediated indirectly by IGF-1,…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Clinical Study of Long-Term Administration of Inpegsomatropin Injection in Participants With Idiopathic Short Stature Who Have Completed Phase Ⅲ Clinical Trials
The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature
Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin (Somatropin) Delivery and Taken up Into the Blood in Healthy Adults
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
Worked on SEROSTIM LQ at Emergent BioSolutions? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on SEROSTIM LQ as LOE approaches offers exposure to defensive commercial strategy, payer negotiations, and lifecycle extension tactics in a mature biologic market. Career growth may be limited compared to growth-stage products, but roles emphasize strategic account management and regulatory intelligence.